scholarly journals HUMAN MENISCUS ALLOGRAFT AUGMENTATION BY ALLOGENEIC MESENCHYMAL STROMAL/STEM CELL INJECTIONS

2021 ◽  
Author(s):  
Caroline Struijk ◽  
Wouter Van Genechten ◽  
Peter Verdonk ◽  
Aaron J. Krych ◽  
Allan B. Dietz ◽  
...  
Keyword(s):  
Stem Cell ◽  
Meniscus Allograft ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell

Mesenchymal Stromal (stem) Cell (MSC) therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury

2021 ◽  
pp. 2004216
Author(s):  
Claudia C. dos Santos ◽  
Hajera Amatullah ◽  
Chirag M. Vaswani ◽  
Tatiana Maron-Gutierrez ◽  
Michael Kim ◽  
...  
Keyword(s):  
Stem Cell ◽  
Lung Injury ◽  
Conditioned Media ◽  
Therapeutic Effects ◽  
Host Immune System ◽  
Gene And Protein Expression ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell ◽  
Deficient Mice

Although mesenchymal stromal (stem) cell (MSC) administration attenuates sepsis-induced lung injury in pre-clinical models, the mechanism(s) of action and host immune system contributions to its therapeutic effects, remain elusive. We show that treatment with MSCs decreased expression of host-derived microRNA (miR)-193b-5p and increased expression of its target gene, the tight junctional protein occludin (Ocln), in lungs from septic mice. Mutating the Ocln 3′ UTR miR-193b-5p binding sequence impaired binding to Ocln mRNA. Inhibition of miR-193b-5p in human primary pulmonary microvascular endothelial cells (HPMECs) prevents tumor necrosis factor (TNF)-induced decrease in Ocln gene and protein expression and loss of barrier function. MSC conditioned media mitigated TNF-induced miR-193b-5p upregulation and Ocln downregulation in vitro. When administered in vivo, MSC conditioned media recapitulated the effects of MSC administration on pulmonary miR-193b-5p and Ocln expression. MiR-193b deficient mice were resistant to pulmonary inflammation and injury induced by LPS instillation. Silencing of Ocln in miR-193b deficient mice partially recovered the susceptibility to LPS-induced lung injury. In vivo inhibition of miR-193b-5p protected mice from endotoxin-induced lung injury. Finally, the clinical significance of these results was supported by the finding of increased miR-193b-5p expression levels in lung autopsy samples from Acute Respiratory Distress Syndrome patients who died with diffuse alveolar damage.

scholarly journals Mesenchymal stromal stem cell therapy in advanced interstitial lung disease - Anaphylaxis and short-term follow-up

Lung India ◽  
2015 ◽  
Vol 32 (5) ◽  
pp. 486 ◽  
Author(s):  
Balamugesh Thangakunam ◽  
DevasahayamJesudas Christopher ◽  
Vikram Mathews ◽  
Alok Srivastava
Keyword(s):  
Stem Cell ◽  
Interstitial Lung Disease ◽  
Cell Therapy ◽  
Lung Disease ◽  
Stem Cell Therapy ◽  
Short Term ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell

Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1

2019 ◽  
Vol 4 (2) ◽  
pp. 127-136 ◽  
Author(s):  
Rebecca Lee ◽  
Nicoletta Del Papa ◽  
Martin Introna ◽  
Charles F Reese ◽  
Marina Zemskova ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Systemic Sclerosis ◽  
Transforming Growth Factor ◽  
Stem Cell Differentiation ◽  
Caveolin 1 ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell ◽  
Domain Peptide ◽  
Stromal Stem Cells

The potential value of mesenchymal stromal/stem cell therapy in treating skin fibrosis in scleroderma (systemic sclerosis) and of the caveolin-1 scaffolding domain peptide in treating lung, skin, and heart fibrosis is known. To understand how these observations may relate to differences between mesenchymal stromal/stem cells from healthy subjects and subjects with fibrosis, we have characterized the fibrogenic and adipogenic potential of adipose-derived mesenchymal stromal/stem cells from systemic sclerosis patients, from mice with fibrotic lung and skin disease induced by systemic bleomycin treatment, and from healthy controls. Early passage systemic sclerosis adipose-derived mesenchymal stromal/stem cells have a profibrotic/anti-adipogenic phenotype compared to healthy adipose-derived mesenchymal stromal/stem cells (low caveolin-1, high α-smooth muscle actin, high HSP47, low pAKT, low capacity for adipogenic differentiation). This phenotype is mimicked by treating healthy adipose-derived mesenchymal stromal/stem cells with transforming growth factor beta or caveolin-1 small interfering RNA and is reversed in systemic sclerosis adipose-derived mesenchymal stromal/stem cells by treatment with caveolin-1 scaffolding domain peptide, but not scrambled caveolin-1 scaffolding domain peptide. Similar results were obtained with adipose-derived mesenchymal stromal/stem cells from systemic sclerosis patients and from bleomycin-treated mice, indicating the central role of caveolin-1 in mesenchymal stromal/stem cell differentiation in fibrotic disease.

scholarly journals Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling

BMC Genomics ◽  
2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Beatriz Roson-Burgo ◽  
Fermin Sanchez-Guijo ◽  
Consuelo Del Cañizo ◽  
Javier De Las Rivas
Keyword(s):  
Stem Cell ◽  
Transcriptomic Profiling ◽  
Cell Identity ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell

scholarly journals Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin in Cardiac Tissue Repair and the Development of Diastolic Dysfunction

2019 ◽  
Vol 125 (4) ◽  
pp. 414-430 ◽  
Author(s):  
Akitoshi Hara ◽  
Hiroki Kobayashi ◽  
Naoya Asai ◽  
Shigeyoshi Saito ◽  
Takahiro Higuchi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Diastolic Dysfunction ◽  
Tissue Repair ◽  
Cardiac Tissue ◽  
Stem Cell Marker ◽  
Cell Marker ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell

scholarly journals Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines

2019 ◽  
Vol 25 (2) ◽  
pp. 149-163 ◽  
Author(s):  
Guido Moll ◽  
James A. Ankrum ◽  
Julian Kamhieh-Milz ◽  
Karen Bieback ◽  
Olle Ringdén ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Clinical Guidelines ◽  
Product Diversification ◽  
Cell Therapy Product ◽  
Stromal Stem Cell ◽  
Mesenchymal Stromal Stem Cell
Sign in / Sign up

Export Citation Format

Share Document